For research use only · Not for human consumption
This material is reference information for laboratory study of research peptides. It is not medical advice and it is not instructions for human use, self-administration, or therapeutic application. Capital Peptides supplies research chemicals for in-vitro and animal-model study only. Discuss any health-related questions with a licensed medical practitioner.
🚫 Warning: This guide is for educational purposes only and is not medical advice. If you have a medical condition, consult a doctor before using any research peptide. The conditions listed below are risk factors, not absolute prohibitions — but they require informed medical oversight.
1. Conditions where avoidance is strongly recommended
| Condition | Which peptides / why |
|---|---|
| Active cancer (any type) | GH secretagogues, IGF-1-raising compounds, and some healing peptides can promote cellular growth — potentially accelerating tumour growth. Avoid GH-axis peptides entirely. |
| Personal history of cancer | Same reasoning — GH/IGF-1 axis activation is a known concern post-treatment. Discuss with your oncologist before any GH-axis peptide. |
| Strong family history of hormone-sensitive cancer | Breast, prostate, endometrial cancers are sensitive to growth hormone and sex hormones. Treat as above. |
| Pregnancy | No safety data exists for any research peptide in pregnancy. The foetal risk is unknown and potentially significant. Do not use. |
| Breastfeeding | Transfer to breast milk is unstudied. Avoid all research peptides. |
| Active retinopathy (eye vessel disease) | GH elevation can worsen diabetic and non-diabetic retinopathy. Avoid GH secretagogues. |
2. Conditions requiring extra caution and monitoring
| Condition | Notes and approach |
|---|---|
| Type 1 or Type 2 diabetes | GH secretagogues can worsen insulin resistance and glucose control. Monitor fasting glucose and HbA1c closely. Start at lower doses. Avoid if glucose control is already poor. |
| Insulin resistance / metabolic syndrome | As above — GH-axis peptides may blunt insulin sensitivity temporarily. Monitor carefully. GLP-1 agonists are a different case and may actually improve metabolic markers. |
| Hypothyroidism or hyperthyroidism | GH signalling interacts with thyroid hormone metabolism. Monitor thyroid function. Dose carefully — both under and overactive thyroid can be destabilised. |
| Autoimmune conditions | Immune-modulating peptides (LL-37, TB-500, Thymosin Alpha-1) can upregulate immune activity. In autoimmune disease where the immune system is already overactive, this could theoretically worsen symptoms. |
| Diagnosed acromegaly or gigantism | Avoid all GH-axis peptides — these conditions already involve excess GH signalling. |
| Carpal tunnel syndrome | GH elevation worsens carpal tunnel. GH secretagogues are a relative contraindication. |
| Oedema or fluid retention disorders | GH-axis peptides commonly cause water retention. In conditions like heart failure, kidney disease, or lymphoedema this can be significant. |
| Benign prostatic hyperplasia (BPH) | GH and androgens can accelerate prostate tissue growth. Monitor PSA if using GH secretagogues long-term. |
| Severe kidney or liver disease | Impaired clearance of peptides and altered protein binding. Dose adjustments and closer monitoring needed. |
3. Common medication interactions
Some commonly prescribed drugs can interact with research peptides:
| Medication class | Peptide concern |
|---|---|
| Insulin / oral hypoglycaemics | GH secretagogues can oppose glucose-lowering effects — blood sugar monitoring is essential |
| Corticosteroids (prednisone, dexamethasone) | Blunt GH release — may reduce the effect of GH secretagogues |
| Thyroid hormone replacement | GH elevation alters T4→T3 conversion — thyroid levels may shift |
| Immunosuppressants (post-transplant, autoimmune) | Immune-modulating peptides can counteract immunosuppression |
| Anticoagulants (warfarin, DOACs) | Some peptides may have mild antiplatelet effects — monitor INR if on warfarin |
| SSRIs / SNRIs | PT-141 (bremelanotide) can interact with serotonergic medications — cardiovascular risk |
4. Getting medically cleared
If you have any of the conditions above, the most practical path is:
- Get comprehensive baseline bloodwork — see the bloodwork guide for what to test.
- Consult your GP. You don't need permission to research — but sharing your plan with a doctor who can review your specific health context is valuable. Many GPs won't prescribe peptides but will monitor bloodwork.
- Choose low-risk compounds first. BPC-157 and ipamorelin have wider safety windows than, say, GHRP-2 or high-dose CJC. Start there if you're managing a health condition.
- Monitor actively. Repeat relevant bloodwork at 6–8 weeks into your cycle. Don't rely on subjective feeling alone.